LIBERATI, Anna Marina
 Distribuzione geografica
Continente #
NA - Nord America 8.552
EU - Europa 7.035
AS - Asia 2.421
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 14
AF - Africa 3
Totale 18.072
Nazione #
US - Stati Uniti d'America 8.516
IE - Irlanda 1.695
UA - Ucraina 1.374
IT - Italia 1.108
SE - Svezia 1.018
SG - Singapore 803
VN - Vietnam 672
HK - Hong Kong 587
FI - Finlandia 504
DE - Germania 450
RU - Federazione Russa 405
CN - Cina 206
GB - Regno Unito 129
FR - Francia 96
CH - Svizzera 66
AT - Austria 55
TR - Turchia 50
UZ - Uzbekistan 36
NL - Olanda 32
KR - Corea 31
AU - Australia 29
RO - Romania 21
CA - Canada 19
EU - Europa 18
GR - Grecia 18
CZ - Repubblica Ceca 17
PL - Polonia 17
LB - Libano 16
MX - Messico 16
BE - Belgio 13
BR - Brasile 10
IN - India 6
ES - Italia 4
BG - Bulgaria 3
ID - Indonesia 3
IL - Israele 3
JP - Giappone 3
PE - Perù 3
IR - Iran 2
MT - Malta 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AL - Albania 1
CL - Cile 1
CR - Costa Rica 1
EG - Egitto 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
PK - Pakistan 1
TN - Tunisia 1
VA - Santa Sede (Città del Vaticano) 1
Totale 18.072
Città #
Dublin 1.693
Chandler 1.371
San Mateo 1.079
Dong Ket 667
Boardman 626
Hong Kong 585
Singapore 530
Altamura 491
Santa Clara 485
Medford 479
Princeton 478
Wilmington 406
Lawrence 371
Andover 351
Jacksonville 312
Perugia 252
Ann Arbor 210
Des Moines 144
Saint Petersburg 136
Norwalk 93
Beijing 91
Ashburn 90
Falls Church 69
San Paolo di Civitate 64
Helsinki 50
Izmir 47
Woodbridge 47
Houston 39
Los Angeles 36
Moscow 33
Shanghai 28
Seoul 23
Vienna 21
Redwood City 20
Rome 20
Dearborn 18
Den Haag 18
Frankfurt Am Main 17
Redmond 17
Port Pirie 16
New York 15
Brussels 13
Bucharest 11
Piediluco 10
Auburn Hills 9
Dallas 9
Munich 9
Tappahannock 9
Lausanne 8
Perth 8
Cambridge 7
Torino 7
Bologna 6
Ottawa 6
Terni 6
Timisoara 6
Assisi 5
Chicago 5
Florence 5
Guangzhou 5
Kiev 5
Milan 5
Ancona 4
Campinas 4
Giacciano con Baruchella 4
Hanover 4
Minneapolis 4
Modena 4
Napoli 4
Pozzuoli 4
Toronto 4
Atlanta 3
Bari 3
Brisbane 3
Ceppaloni 3
Chalco 3
Chengdu 3
Foligno 3
Fremont 3
Hanoi 3
Merate 3
Nürnberg 3
Palermo 3
Philadelphia 3
Seodaemun-gu 3
Simi Valley 3
Surabaya 3
Winnipeg 3
Zhengzhou 3
Arad 2
Athlone 2
Belém 2
Berlin 2
Bordeaux 2
Bratislava 2
Brno 2
Buffalo 2
Callao 2
Corciano 2
Costa Mesa 2
Totale 11.804
Nome #
WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) 130
Integration of Traditional and Western Medicine in Vietnamese Populations: A Review of Health Perceptions and Therapies 127
[Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report]. 94
Artocarpus tonkinensis protects mice against collagen-induced arthritis and decreases Th17 cell function 94
Maesopsin 4-O-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN! and BCAS3 in acute myeloid leukemia 86
Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome? 85
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. 85
Cell membrane markers and phytohemagglutinin reactivity of circulating lymphocytes from chronic myelocytic leukemia patients. 83
Anti-cancer activity of compounds isolated from Bursera microphylla 83
Prognosi e terapia del mieloma multiplo. 82
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. 81
L'interferone alfa nella leucemia mieloide cronica 81
67Ga scan detects residual active disease and it is predictive of disease-free survival in malignant lymphoma patients 80
67Ga scan detects residual active disease and it is predictive of disease-free survival in malignant lymphoma patients. 80
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 80
Evaluation of response to therapy with 67Ga scintigraphy, CT scan and magnetic resonance in malignant lymphomas. 80
Anti-rheumatoid arthritis activity of decoction from the leaves of the tree Artocarpus tonkinensis used in Vietnamese traditional medicine 79
SUMO proteins: Guardians of immune system 77
Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. 76
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients 74
All-trans-retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 74
Indicazione all’autotrapianto in prima linea nel linfoma non-Hodgkin’s aggressivo. 73
Anti-cancer activity of compounds isolated from Bursera microphylla. 73
Monitoring treatment and survival in chronic myeloid leukemia. 72
67Ga-scan detects residual active disease and it is predictive of disease-free survival in classical Hodgkin's disease patients 72
Myelomonocytic-associated antigens in a case of genotypically, phenotypically and functionally B-cell lymphoma. 72
R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit“ patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL) 72
Isolation and identification of bioactive molecules from resins used in traditional medicine: Commiphora erythraea and Bursera microphylla 72
Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients. 71
Fattori prognostici nel carcinoma colon-retto. 71
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. 71
The role of autotransplantation in chronic lymphocytic leukemia and results from the italian group. 70
Complex translocations of the Ph chromosome and Ph-negative CML arise from similar mechanisms as evidenced by FISH analysis. 70
Effectiveness and Safety of Combined Cytoreductive Therapy In 56 Patients With Essential Thrombocythaemia: Report of the Registro Italiano Trombocitemie (rit) 69
Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients 69
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. 68
Pharmacological modulation of caspase-8 in thymus-related medical conditions. 68
Conventional induction treatments do not influence overall survival in multiple myeloma. 67
In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients. 67
GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. 67
Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. 66
Staging of chronic myeloid leukaemia. 66
Rare immunological presentation in B-cell chronic lymphocytic leukaemia. 66
A 4-day chemosensitivity assay in vitro reliably predicts clinical response of patients with acute leukemia 66
Lenalidomide and its role in the management of multiple myeloma. 66
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer. 66
Pharmacologic and immunologic effects of human leukocyte interferons in patients with neoplasia: an interim report. 65
67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma 64
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. 64
Bcl-xL overexpression decreases GILZ levels and inhibits glucocorticoid-induced activation of caspase-8 and caspase-3 in mouse thymocytes 64
Pre-autologous stem cell transplantation (ASCT) treatment with rituximab does not impair stem cell harvest and engraftment in untreated patients with diffuse large B-cell lymphoma (B-DLCL) at poor prognosis 63
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD) 62
Melphalan 200 mg/m2 versus Melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multi-center phase III study. 62
Interferon Alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent administration. 62
Effect of adding Rituximab to intensified and high dose chemotherapy(HDC)with ASCT as first line treatment in stage III-IV at intermediate-high (IH) and high risk (HR) diffuse large B-cell lymphoma 62
Treatment of Ph-positive Chronic Myeloid Leukemia with alpha-Interferon (Roferon-A). The Italian Cooperative Study Group experience. 62
Long term outcome of Ph plus CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 61
Addition of rituximabto dose-denseand high dose chemotherapy with autologous transplantation in untreated poor-prognosis diffuse large B-cell lymphoma: Results of phase II trial 60
Fusarubin and anhydrofusarubin isolated from a Cladosporium species inhibit cell growth in human cancer cell lines 60
Has 67Ga-scan a role in the evaluation of lymphoma response to conventional or high dose chemotherapy? 59
Interferon-alpha-2b as therapy for untreated and pretreated patients with Ph' positive chronic myeloid leukemia 59
Allogeneic hematopoietic stem cell transpalntation in children and adolescent with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. 59
A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis. 59
L’approccio terapeutico nell’anziano con mielodisplasia. 59
67Ga-scan usefulness in predicting the clinical outcome and the long-term effects of chemotherapy in lymphoma patients 58
Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma. 58
A brief course of chemo-immunotherapy FND plus rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis. 58
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients? 58
A case of acute myeloid leukemia with deletion of chromosome 7 following PBSC transplantation. 57
Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT) 57
A Prospective Randomized Trial of Bortezomib-melphalan-prednisone-thalidomide Followed By Continuous Bortezomib-thalidomide For Initial Therapy of Multiple Myeloma: Effect of Age and Co-morbidities 57
Ph '-positive (Ph '+) chronic myeloid leukemia (CML) presenting as Ph ' plus T-lymphoblastic lymphoma (LL) resistant to high-dose chemotherapy and Gleevec. 56
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. 56
Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients 56
Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy. 56
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer. 56
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD) 56
Citotossicità spontanea in pazienti con B-LLC. 56
Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no transplant in cohort of 258 patients first seen in Italy between 1984 and 1986. 56
Evaluation of response therapy with 67Ga scintigraphy, CT scan and magnetic resonance in malignant lymphomas. 55
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: A preliminary experience. 55
Chronic Myeloid Leukemia In Blast Crisis Treated With Imatinib 600 Mg: Outcome of the Patients Alive After A 6-year Follow-up 55
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis. 55
La scintigrafia ossea nella diagnosi e nel "follow-up" del carcinoma mammario. 55
A prospective randomized controlled trial of oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients 55
Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma. 55
Role of microRNAs in the activity of new therapeutic inhibitors of Src kinases in CD133+ colorectal cancer cells 55
Differences among young adults, adults and elderly chronic myeloid leukemia patients 55
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. 54
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. 53
L'interferone nel trattamento della leucemia mieloide cronica Philadelphia positiva. 53
Esordio apparentemente cutaneo di linfoma maligno a linfociti B e cellule nulle. 53
The value of molecular response in chronic myeloid leukaemia: the present and the future. 53
The therapeutic effect of new Src inhibitor in colon cancer cells and potential role of mir494. 53
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases 52
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution 52
Electrophysiological and neuropsychological functions in patients treated with interferon-beta. 52
Immunologic profile in patients with Hodgkin's disease in complete remission. 52
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 52
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma 52
Totale 6.624
Categoria #
all - tutte 92.789
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.789


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020639 0 0 0 0 0 11 115 4 367 49 22 71
2020/20213.377 13 317 116 310 1.037 202 99 24 242 108 169 740
2021/20223.652 63 696 57 123 125 55 63 1.377 39 67 385 602
2022/20235.594 512 1.044 31 395 402 609 7 253 2.147 6 151 37
2023/20241.834 137 213 107 32 20 15 555 26 80 67 244 338
2024/20251.488 47 548 89 125 569 110 0 0 0 0 0 0
Totale 19.338